Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Preclinical evaluation of SWI/SNF targeting agents in multiple myeloma including t(4;14) subtypes

Yusuke Yamashita, Jonathan Patton, Yuliza Shotts et al. Nov 03, 2025 pp. 2138-2138 10.1182/blood-2025-2138

Abstract Introduction: Despite remarkable advances in treatment, patients with multiple myeloma (MM) continue to suffer relapse. Therefore,...

Longitudinal single-cell profiling in canine DLBCL reveals regulatory networks driving chemotherapy resistance.

Steven Tur, Yinghua Wang, Peng Liu et al. Nov 03, 2025 pp. 1788-1788 10.1182/blood-2025-1788

Abstract Diffuse Large B Cell Lymphoma (DLBCL) is the most common lymphoid malignancy in both humans and dogs, characterized by clinical and...

Impact of hereditary predisposition genes to hematologic malignancies on transplant outcomes and donor selection

Zhihui Li, Qinlong Zheng, Keyan Yang et al. Nov 03, 2025 pp. 1053-1053 10.1182/blood-2025-1053

Abstract Impact of Hereditary Predisposition Genes to Hematologic Malignancies on Transplant Outcomes and Donor Selection Background: With t...

Real-world treatment patterns and outcomes among patients with newly diagnosed NPM1-mutated acute myeloid leukemia in the United States

Kuo-Kai Chin, Grace Gahlon, Lorena Lopez-Gonzalez et al. Nov 03, 2025 pp. 3385-3385 10.1182/blood-2025-3385

Abstract Introduction: Approximately 30% of adults with acute myeloid leukemia (AML) have nucleophosmin 1 mutations (NPM1m). However, standar...

Better outcomes with haploidentical than matched sibling donors for adult AML patients allo-transplanted in CR with detectable MRD: A study from the global committee and the ALWP of the EBMT.

Yishan Ye, Jacques-Emmanuel Galimard, Myriam Labopin et al. Nov 03, 2025 pp. 1059-1059 10.1182/blood-2025-1059

Abstract Background Disease relapse is a major challenge for acute myeloid leukemia patients after allogeneic hematopoietic cell transplanta...

Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients

Matteo Molica, Gema Miralles, Richard Dillon et al. Nov 03, 2025 pp. 1662-1662 10.1182/blood-2025-1662

Abstract Background: Gilteritinib is a selective FLT3 inhibitor approved for the treatment of relapsed or refractory (R/R) FLT3-mutated acut...

Understanding health literacy among patients with thalassemia: Results from a global patient survey by the Thalassemia Advocacy Advisory Council

Sujit Sheth, Lily Cannon, Laurice Levine et al. Nov 03, 2025 pp. 6421-6421 10.1182/blood-2025-6421

Abstract Introduction: Despite advances in the management of thalassemia, a rare and under-recognized hereditary anemia, unmet needs remain...

Successful melphalan flufenamide (melflufen) therapy in patients with severe renal insufficiency

Klaus Fenchel, Gesa Geuther, Wolfram Dempke Nov 03, 2025 pp. 7521-7521 10.1182/blood-2025-7521

Abstract Background: Multiple myeloma (MM) is a malignant and heterogenous plasma cell disorder. It is characterized by the clonal prolifera...

Mass spectrometry demonstrates very frequent multi-clonality in familial Waldenström macroglobulinemia and shows distinct IgM profiles across IgM-related disorders.

Alberto Guijosa, Nickolas Tsakmaklis, Abigail Peachey et al. Nov 03, 2025 pp. 5392-5392 10.1182/blood-2025-5392

Abstract Introduction: Waldenström macroglobulinemia (WM) is clinically heterogeneous with a subset of patients experiencing IgM-driven comp...

The T cell immunosenescence profile of patients with newly diagnosed multiple myeloma as an indicator of frailty: Preliminary data from the immuno-NDMM protocol.

Stefano Crippa, Alessandra Perego, Sarah Tettamanti et al. Nov 03, 2025 pp. 5786-5786 10.1182/blood-2025-5786

Abstract BACKGROUND Fit and young (< 65 years) patients (pts) with newly diagnosed Multiple Myeloma (NDMM) are candidates to high dos...

Improved hematopoietic stem cell mobilization for gene therapy using single agent motixafortide in sickle cell disease

Stephan Grupp, Michael Grimley, Timothy Driscoll et al. Nov 03, 2025 pp. 2542-2542 10.1182/blood-2025-2542

Abstract While the development and approval of gene therapies (GT) for sickle cell disease (SCD) has transformed treatment options for patie...

Effect of pre-allogeneic HCT splenic irradiation on post-transplant engraftment and outcomes in patients with myelofibrosis: A single-center experience

Yenny Moreno Vanegas, Ahmed Abdelhakeem, Madiha Iqbal et al. Nov 03, 2025 pp. 5984-5984 10.1182/blood-2025-5984

Abstract Background: Allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative option for myelofibro...

Current practices of anticoagulant utilization in pediatric patients with acute myeloid leukemia (AML)

Abbey Elsbernd, Natalie Grills, James Antoon et al. Nov 03, 2025 pp. 1342-1342 10.1182/blood-2025-1342

Abstract Introduction: Management of thromboembolism (TE) in pediatric acute myeloid leukemia (AML) is challenging due to prolonged periods...

Quality-adjusted survival analysis of neurologic events with ciltacabtagene autoleucel (Cilta-cel) vs standard of care (SOC) in patients (Pts) with lenalidomide-refractory multiple myeloma (MM) who received 1–3 prior lines of therapy (LOT): Cartitude-4 trial population (Pop)

Surbhi Sidana, Leyla Shune, Luciano Costa et al. Nov 03, 2025 pp. 5768-5768 10.1182/blood-2025-5768

Abstract Introduction: A single infusion of cilta-cel demonstrated significant improvement in overall survival (OS) vs SOC in pts with lenal...

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: a DESCAR-T Registry and International Collaborative Study

Eric Durot, Lukshe Kanagaratnam, Sylvain Choquet et al. Nov 03, 2025 pp. 5490-5490 10.1182/blood-2025-5490

Abstract Introduction: The prognosis of patients (pts) with histological transformation (HT) of Waldenström macroglobulinemia (WM) remains d...

Downregulation of TANK gene affects erythroid differentiation in PNH patients.

Liyan Li, Zewei Chen, Hui Liu et al. Nov 03, 2025 pp. 1106-1106 10.1182/blood-2025-1106

Abstract Background:Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disease of hematopoietic stem cells characterized by com...

Clonal hematopoiesis and immune dysregulation in classic PNH

Jinhui Ye, Xiaohuan Qin, Xueling Li et al. Nov 03, 2025 pp. 3208-3208 10.1182/blood-2025-3208

Abstract Introduction Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder originating from somatic mutations in PIGA wit...

Temporal trends in mortality from hematological cancers with atrial fibrillation and flutter as contributing causes in the United States, 2000–2020: A national vital statistics system analysis

Manas Pustake, Kunal Sharma, Lakshmi Kattamuri et al. Nov 03, 2025 pp. 6404-6404 10.1182/blood-2025-6404

Abstract Background: Hematological malignancies pose a significant public health burden, with atrial fibrillation/flutter (AF/AFL) increasin...

Bone marrow immune and stromal niche remodeling in myelodysplastic neoplasm patients under erythropoietic therapies by 29-color full-spectrum flow cytometry

Claudia Pellin Jou, Iñaki Salvador Corres, Pamela Acha et al. Nov 03, 2025 pp. 3183-3183 10.1182/blood-2025-3183

Abstract INTRODUCTION Despite immune and stromal components of the bone marrow (BM) niche are increasingly recognized as key regulators in my...

Antiplatelet therapy in anticoagulated cirrhotic patients with chronic portal vein thrombosis: A retrospective multicenter study

Gary Batra, Tiantian Zhang, Anil Harrison et al. Nov 03, 2025 pp. 3129-3129 10.1182/blood-2025-3129

Abstract Background: Treatment of chronic portal vein thrombosis (PVT) in cirrhotic patients can be complicated, mainly...

Optimizing establishment of high need pediatric Acute Myeloid Leukemia (AML) patient derived xenograft (PDX) models

Lana Kim, Max Rochette, Shivani Gollapudi et al. Nov 03, 2025 pp. 1515-1515 10.1182/blood-2025-1515

Abstract Introduction: Pediatric acute myeloid leukemia (pAML) patient-derived xenograft (PDX) models are vital for pre-clinical evaluation...

Elucidating the role of retrotransposon-mediated viral mimicry in leukemia therapy

Syed Ahmad, Kaili Wang, Michael Lee et al. Nov 03, 2025 pp. 774-774 10.1182/blood-2025-774

Abstract Hypomethylation agents (HMA), including 5-azacytidine (AZA) and decitabine (DAC), are frontline therapies for myelodysplastic syndr...

Isatuximab subcutaneous in relapsed/refractory multiple myeloma: Exposure-response and serum m-protein dynamics analyses from phase 3 iraklia Study and the phase 1b Study

Nadia Gaudel, Hoai-Thu Thai, Kamilia Abdelraouf et al. Nov 03, 2025 pp. 5826-5826 10.1182/blood-2025-5826

Abstract Introduction: The first Phase (Ph) 3 study in multiple myeloma (MM) using an on-body injector (OBI), IRAKLIA (NCT05405166), is a ra...

Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab

Bhavana Bhatnagar, Zhuoxin Sun, Ryan Mattison et al. Nov 03, 2025 pp. 1549-1549 10.1182/blood-2025-1549

Abstract Background: The addition of the CD19/CD3 bispecific T-cell engager, blinatumomab, to standard consolidation chemotherapy in adults...

Impact of high-dose methotrexate in both central nervous system relapse and systemic progression in high-risk DLBCL: A retrospective analysis of a brazilian cohort

Paloma Resende, Andre Meireles, Wysterlanyo Kayo Barros et al. Nov 03, 2025 pp. 3673-3673 10.1182/blood-2025-3673

Abstract Background: Central nervous system (CNS) relapse in diffuse large B-cell lymphoma (DLBCL) is a rare but devastating event, with dism...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page